UK markets closed

Sartorius Stedim Biotech S.A. (0RG8.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
367.44+27.78 (+8.18%)
At close: 06:45PM BST
Currency in EUR

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.64
52-week change 3N/A
S&P500 52-week change 326.14%
52-week high 3354.90
52-week low 3338.90
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 829.29M
% held by insiders 169.71%
% held by institutions 113.41%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 26:1
Last split date 306 May 2016

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 9.38%
Operating margin (ttm)16.49%

Management effectiveness

Return on assets (ttm)3.92%
Return on equity (ttm)8.15%

Income statement

Revenue (ttm)2.72B
Revenue per share (ttm)29.09
Quarterly revenue growth (yoy)-8.20%
Gross profit (ttm)N/A
EBITDA 635.8M
Net income avi to common (ttm)254.7M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)-49.50%

Balance sheet

Total cash (mrq)695.1M
Total cash per share (mrq)7.19
Total debt (mrq)3.19B
Total debt/equity (mrq)82.46%
Current ratio (mrq)2.13
Book value per share (mrq)39.62

Cash flow statement

Operating cash flow (ttm)636.2M
Levered free cash flow (ttm)27.25M